2Achievements during the Bone and Joint Decade 2000–2010
Introduction
The Bone and Joint Decade was established to draw attention to the major problems of musculoskeletal diseases and trauma around the globe and to stimulate education and research leading to better care and clinical outcomes for patients with musculoskeletal diseases. Target conditions for the decade included
- •
joint disease
- •
osteoporosis
- •
back pain and spine conditions
- •
childhood musculoskeletal conditions
- •
road traffic trauma
Although we are well aware of the burden of musculoskeletal conditions, we forget that every minute of every day a child is killed or seriously injured on the worlds roads. Many of these deaths and injuries are preventable and this has been a major focus of this decade.
From a medical perspective, this decade has seen great advances in the management of inflammatory forms of arthritis driven in part by the wider availability of the biologic agents which have increased in range and number. Biologics are also showing benefit in a greater number of diseases such as ankylosing spondylitis, psoriatic arthritis and connective tissue diseases [1], [2].
Osteoarthritis is increasing with the ageing population and is the major reason for mobility restriction. Despite significant efforts over the past decade to develop markers for early detection, there is still no clear way of identifying which patients will progress rapidly [3]. Treatment remains symptomatic with a combination of pharmaceutical and physiotherapy approaches along with general issues such as maintaining ideal body weight.
Although non-steriodal anti-inflammatory drugs are still the mainstay of treatment for many painful musculoskeletal conditions, there is growing concern about the evidence that all non-steroidal anti-inflammatory drugs (NSAIDs) are associated with an increase in the risk of cardiovascular disease [4]. Musculoskeletal pain is still the most common symptom that afflicts humankind and its management needs to be improved significantly [5].
New osteoporotic agents have also been developed [6] but the standard therapies such as the bisphonates have come under some shadow because of side effects such as bone destruction [7].
All of these advances combine to provide patients with musculoskeletal disease with a more positive message in 2010 than at the beginning of the decade in the year 2000 [8]. So, how has this occurred and how will it be maintained?
The establishment of National Action Networks in nearly 62 countries around the globe has surely raised the profile of these conditions nationally and internationally. Unfortunately, one of our major sponsors – the World Health Organisation (WHO) – has still not recognised musculoskeletal conditions as a priority area despite the overwhelming evidence of their impact on the burden of the disease [9].
Section snippets
Milestones in the Bone and Joint Decade [10]
This table summarises the major activities of the decade.
- •
1998 Inaugural Consensus Meeting held in Lund, Sweden to establish goals and objectives of the Bone and Joint Decade (BJD).
- •
1999 United Nations endorses BJD 2000–2010.
- •
2000 BJD formally launched at WHO in Geneva.
- •
2000 The first BJD world Network Meeting held in Oman and repeated each year
- -
2002 Brazil
- -
2003 Germany
- -
2004 China
- -
2005 Canada
- -
2006 South Africa
- -
2007 Australia
- -
2008 India
- -
2009 USA
- -
2010 Sweden
- -
- •
2003 Global Technical report published by WHO: The
Minimally invasive surgery
Minimally invasive surgery has been the operative signature of the 21st century. The desire to reduce the morbidity of surgery, postoperative pain and length of in-hospital stay has resulted in many innovative ways to perform elective and acute orthopaedic procedures. Examples where minimally invasive surgery has been most successfully deployed include hip [13], [14] and knee [15] replacement surgery, shoulder stabilisation procedures, decompression of rotator cuff impingement [16], [17], [18],
Bioengineering
The growth in interest in cell and tissue repair, regeneration and re-engineering has been the foundation for a ground swell of research into bioengineering [34]. Orthopaedics is a discipline ideally suited to benefit from the outcomes of this research. The need for innovative answers to osteoarticular bone loss from trauma, tumour or degeneration is a prime example of where the efforts in bioengineering can be directed. Already considerable amounts of work have been done looking at ways of
Robotics
Robotics is an exciting area not only as an instrument to undertake more accurate surgery [37] but also as a means of replacing lost limbs. Robotics as a tool for surgery has enjoyed mixed receptions. The complexity of the architecture and computer interfaces together with the overall size, and cost of the machinery has meant that early uptake of this technology was limited. Initially used to assist in joint replacement ‘robodoc’ was an instrument that could precisely mill out bone from the
Joint replacement registries
One of the most important outcomes of the internationality of orthopaedics is the development of national joint replacement registries [41], *[42]. Joint replacement surgery is an exemplar of high-volume high-cost surgery and the need for such surgery in an ageing population is expected to rise dramatically over the next two decades. With the anticipated cost of this surgery to exceed tens of billions of dollars each year, joint replacement surgery will have a significant impact on health
Conclusions
The management of musculoskeletal disease and trauma is becoming ever more complex. Surgeons, physicians, rehabilitationists, nurses and allied health professionals, to name but a few, are involved along with patients and their families. It is one of the best examples in health of ‘team’ care – health professionals of many disciplines working with patients to improve outcomes. Patient involvement has been one of the major platforms of the BJD and will be even more significant in the next
References (43)
- et al.
Rheumatoid arthritis
Lancet
(2010) - et al.
Spondyloarthritis
Lancet
(2011) - et al.
Osteoarthritis: an update with relevance for clinical practice
Lancet
(2011) - et al.
Treatment of non-cancer pain
Lancet
(2011) - et al.
Osteoporosis: now and the future
Lancet
(2011) - et al.
Arthroscopic repair of anterior glenohumeral instability and rotator interval lesions
Orthopaedic Clinics of North America
(2003 Oct) - et al.
The two-incision minimally invasive total hip arthroplasty: technique and results
Orthopaedic Clinics of North America
(2004 Apr) The ugly underbelly of the MIS movement: in the affirmative
Journal of Arthroplasty
(2007 Jun; 22)Minimally invasive total hip arthroplasty: in opposition
Journal of Arthroplasty
(2004 Jun; 19)- et al.
Does accurate anatomical alignment result in better function and quality of life? Comparing conventional and computer-assisted total knee arthroplasty
Journal of Arthroplasty
(2009 Jun)
Conducting polymers for neural interfaces: challenges in developing an effective long-term implant
Biomaterials
Cardiovascular safety of NSAIDs
British Medical Journal
The role of bisphosphonates in the management of postmenopausal osteoporosis: an update on safety anxieties
Menopause International
The bone and joint decade 2000–2010
Journal of Rheumatology
The burden of musculoskeletal disease - a global perspective
Clinical Rheumatology
Society for padiatric research - 2007 Presidential address: expanding the research continuum –from bench to implementation
Pediatric Residency
The impact of chronic illness: partnerships with other health professionals
Medical Journal of Australia
Making minimally invasive THR safe: conclusions from biomechanical simulation and analysis
International Orthopaedics
Minimally invasive total hip replacement via the anterolateral approach in the supine position
International Orthopaedics
The immediate effect of navigation on implant accuracy in primary mini-invasive unicompartmental knee arthroplasty
Knee Surgery, Sports Traumatology Arthroscopy
Cited by (13)
A model for facilitating translational research and development in China: Call for establishing a Hong Kong Branch of the Chinese National Engineering Research Centre for Biomaterials
2014, Journal of Orthopaedic TranslationCitation Excerpt :The resulting clinical or market demand for high-quality orthopaedic biomaterials for clinical applications is very substantial. According to official statistics, 100 million patients have osteoarthritis; as many as 300–400 million patients have tooth defects and tooth loss; 70 million patients have osteoporosis; nearly 10 million patients each year have bone defects caused by illness, accidents, and sports injuries; and tens of millions of people require craniofacial and breast cosmetic plastic surgeries [5,6]. The treatment of these diseases requires biomaterials, thus creating a huge market for the biomaterial industry.
Innovation in Orthopedics: Part 1—Design Thinking
2022, Current Reviews in Musculoskeletal MedicineMental disorders, musculoskeletal disorders and income-driven patterns: Evidence from the global burden of disease study 2017
2020, Journal of Clinical MedicineRadiotherapy for benign diseases of the human musculoskeletal system: A review
2020, Tagliche PraxisRadiotherapy for benign diseases of the human musculoskeletal system: A review
2019, Internistische PraxisReducing the global burden of musculoskeletal conditions
2018, Bulletin of the World Health Organization